CSIMarket
 
Olema Pharmaceuticals inc   (OLMA)
Other Ticker:  
 
 
Price: $11.5500 $-0.02 -0.173%
Day's High: $12.14 Week Perf: -11.15 %
Day's Low: $ 11.22 30 Day Perf: -23.26 %
Volume (M): 5,010 52 Wk High: $ 17.79
Volume (M$): $ 57,870 52 Wk Avg: $10.33
Open: $12.14 52 Wk Low: $3.00



 Market Capitalization (Millions $) 519
 Shares Outstanding (Millions) 45
 Employees 30
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -96
 Cash Flow (TTM) (Millions $) 91
 Capital Exp. (TTM) (Millions $) 0

Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc. is a clinical stage biopharmaceutical company that focuses on the development of novel cancer therapies. The company is headquartered in San Francisco, California and was founded in 201 Its mission is to develop innovative therapies that can improve the lives of patients who are suffering from cancer, by identifying and targeting cancer-specific vulnerabilities.

Olema's flagship drug candidate is known as OP-1250. It is a first-in-class small molecule that targets the estrogen receptor (ER) alpha and covalently binds to a cysteine residue to create a unique pharmacological profile that leads to sustained anti-tumor activity across multiple tumor types. The company believes that OP-1250 could become a superior estrogen receptor antagonist compared to existing drugs on the market, especially in breast cancer treatment.

Olema's research is based on the unique biology of cancer and how tumor cells grow and respond to different stimuli. The team at Olema is focused on developing targeted therapies that will be effective against specific types of cancers. In addition to its work on OP-1250, Olema is also developing other small molecule drugs simultaneously.

The CEO of Olema is Sean P. Bohen, M.D., Ph.D., who has over 20 years of experience in the pharmaceutical industry, including leadership roles at companies like AstraZeneca, Merck, and Genentech. He has assembled a strong team of experts in oncology drug development, clinical research, and regulatory affairs to help achieve Olema's goals.

As of August 2021, Olema Pharmaceuticals Inc. had a market capitalization of about $8 billion. The company has raised over $507 million in equity financing as well as receiving grants and awards from public and private entities.

In summary, Olema Pharmaceuticals Inc. is a clinical-stage company focused on developing targeted therapies for cancer treatment, with its leading drug candidate, OP-1250. The company has a strong management team, a solid research pipeline, and has received significant financial support from investors and from public and private grants. Olema is committed to bringing innovative therapies to patients living with cancer, making a difference in the world by improving treatments for cancer.


   Company Address: 780 Brannan Street San Francisco 94103
   Company Phone Number: 243-5555   Stock Exchange / Ticker: NASDAQ OLMA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Palazestrant: A Promising Therapeutic Approach for ER+ Breast Cancer Treatment

Published Wed, Mar 6 2024 12:03 PM UTC

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in targeted therapies for women's cancers, has announced the publication of an important data article in Molecular Cancer Therapeutics. The article explores the unique characteristics of palazestrant (OP-1250) and its potential efficacy in inhibiting both wild-type and mutant ER-positive (ER+) bre...

Clinical Study

Olema Oncology's Palazestrant Shows Promising Potential in Combination with CDK4/6 Inhibitors Ribociclib and Palbociclib in Ongoing Clinical Trials

Published Tue, Dec 5 2023 5:28 PM UTC



San Francisco-based biopharmaceutical company Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), also known as Olema Oncology, is making waves in the field of women's cancers with its latest announcement. The company has revealed interim results from their ongoing Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitors ribociclib and palb...

Financing Agreement

Olema Oncology Empowers Talent with Inducement Grants, Fueling Breakthroughs in Women's Cancer Treatment

Published Mon, Dec 4 2023 9:29 PM UTC

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 04, 2023 - Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a leading clinical-stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for women's cancers, announced today the issuance of stock options to three new employees. These...

Clinical Study

Unveiling the Future of HR-Positive Breast Cancer Treatment: Olema Oncology Reveals Groundbreaking Data on Palazestrant in Combination Therapy at SABCS 2023

Published Tue, Nov 28 2023 10:10 PM UTC

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Olema Oncology, a leading biopharmaceutical company dedicated to developing targeted therapies for women with hormone receptor-positive (HR-positive) breast cancer, is set to present groundbreaking clinical data at the upc...

Olema Pharmaceuticals Inc

Major Pharmaceutical Preparations Company Faces Operating Shortfall, But Optimism Grows for Future Success

Financial News Report: Olema Pharmaceuticals Reports Operating Shortfall but Shows Promise in Diminishing Returns
During the earnings season from July to September 30, 2023, numerous companies have released their financial results. Among them are several companies in the Major Pharmaceutical Preparations sector, including OLMA. OLMA recently reported an operating shortfall of $-23.342 million for the same time frame. However, stakeholders are optimistic about the potential of a new business model in the upcoming cycle. Shareholders appear to be less concerned about the current organizational and operational performance of the Major Pharmaceutical Preparations company.
One positive note is that the diminishing returns of OLMA decreased to $-21.502 million from $-22.720 million in the third quarter of 2022. This improvement should support the organization on its path to becoming a standout player in the industry. Investors will be eagerly awaiting OLMA Pharmaceuticals' next financial report, which is expected to be released on March 08, 2024.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com